Sökning: id:"swepub:oai:DiVA.org:uu-397685" >
Allogeneic stem cel...
Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era : population-based data from the Swedish CML registry
-
- Lubking, Anna (författare)
- Skane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Lund, Sweden
-
- Dreimane, Arta (författare)
- Linköpings universitet,Institutionen för klinisk och experimentell medicin,Medicinska fakulteten,Region Östergötland, Hematologiska kliniken US
-
- Sandin, Fredrik (författare)
- Uppsala Univ Hosp, Reg Canc Ctr, Uppsala, Sweden
-
visa fler...
-
- Isaksson, Cecilia (författare)
- Umea Univ Hosp, Dept Hematol, Umea, Sweden
-
- Markevarn, Berit (författare)
- Umea Univ Hosp, Dept Hematol, Umea, Sweden
-
- Brune, Mats (författare)
- Sahlgrens Univ Hosp, Dept Hematol & Coagulat, Gothenburg, Sweden
-
- Ljungman, Per (författare)
- Karolinska Institutet,Karolinska Univ Hosp, Sweden; Karolinska Inst, Sweden
-
- Lenhoff, Stig (författare)
- Skane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Lund, Sweden
-
- Stenke, Leif (författare)
- Karolinska Institutet,Karolinska Univ Hosp Solna, Sweden
-
- Höglund, Martin (författare)
- Uppsala universitet,Hematologi,Uppsala Univ Hosp, Sweden
-
- Richter, Johan (författare)
- Skane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Lund, Sweden
-
- Olsson-Strömberg, Ulla (författare)
- Uppsala universitet,Hematologi,Uppsala Univ Hosp, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2019-04-08
- 2019
- Engelska.
-
Ingår i: Bone Marrow Transplantation. - : Springer Science and Business Media LLC. - 0268-3369 .- 1476-5365. ; 54:11, s. 1764-1774
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Two decades after the introduction of tyrosine kinase inhibitors (TKI), a sizeable portion of patients with chronic myeloid leukemia (CML) in chronic phase (CP) still undergo allogeneic stem cell transplantation (allo-HSCT). We investigated the indications for allo-HSCT, clinical outcome, management of relapse, and post-transplant TKI treatment in a population-based setting using the Swedish CML registry. Of 118 CML patients transplanted between 2002 and 2017, 56 (47.4%) received allo-HSCT in first CP, among whom TM resistance was the most common transplant indication (62.5%). For patients diagnosed with CML in CP at <65 years of age, the cumulative probability of undergoing allo-HSCT within 5 years was 9.7%. Overall 5-year survival was 96.2%, 70.1% and 36.9% when transplanted in first CP, second or later CP, and in accelerated phase or blast crisis, respectively. Risk factors for relapse were EBMT score >2 and reduced intensity conditioning, and for death, CP > 2 at time point of allo-HSCT only. Non-relapse mortality for patients transplanted in CP was 11.6%. Our data indicate that allo-HSCT still constitutes a reasonable therapeutic option for patients with CML in first CP, especially those resistant to TKI treatment, providing high long-term survival and low non-relapse mortality.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Lubking, Anna
-
Dreimane, Arta
-
Sandin, Fredrik
-
Isaksson, Cecili ...
-
Markevarn, Berit
-
Brune, Mats
-
visa fler...
-
Ljungman, Per
-
Lenhoff, Stig
-
Stenke, Leif
-
Höglund, Martin
-
Richter, Johan
-
Olsson-Strömberg ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
- Artiklar i publikationen
-
Bone Marrow Tran ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet
-
Linköpings universitet